



CONTENT FROM VIATRIS

PROFILE 2021 | FORTUNE 500

Working to Redefine Health Care

Global pharmaceutical company **Viatis** is betting that its infrastructure and expertise can help partners get medicines to more patients and markets worldwide.

VIATRIS, CREATED FROM THE

consolidation of Mylan and Pfizer's legacy Upjohn unit, was formed in November 2020. It could not have emerged at a more necessary time—during a worldwide pandemic.

"More than ever, governments, patients, and health care systems are seeking access to high-quality medicines and innovative solutions," says Michael Goettler, Viatis CEO. The company's global vision of providing the broadest possible access to trusted medications, regardless of geography or circumstance, is aimed squarely at meeting those demands.

"OUR COMPANIES COMBINED IN A REALLY COMPLEMENTARY WAY. TOGETHER, AS VIATRIS, WE HAVE ALL THE REQUISITE ASSETS UNDER ONE ROOF AND HAVE BUILT A POWERFUL BUSINESS PLATFORM SET UP FOR FUTURE GROWTH."

ROBERT J. COURY
EXECUTIVE CHAIRMAN, VIATRIS

"BIOTECH COMPANIES ARE PLAYING A CRITICAL ROLE IN HEALTH CARE TODAY. VIATRIS CAN BE THEIR PARTNER OF CHOICE™ TO ACCELERATE PATIENT ACCESS TO THEIR INNOVATIONS IN ALL CORNERS OF THE WORLD."

MICHAEL GOETTLER
CEO, VIATRIS

Viatis has already addressed challenges specific to COVID-19, such as ramping up production of the antiviral medication remdesivir and working with government authorities in India to expand access to important medicines. But the U.S.-based company, which offers more than 1,400 approved molecules across a wide range of therapeutic areas in more than 165 countries and territories, is positioned to do much more.

Mylan brought a strong product pipeline and diversified portfolio to the merger that formed Viatis, and Upjohn offered a meaningful presence in China, says Robert J. Coury, executive chairman of Viatis. "Our companies combined in a really complementary way. Together, as Viatis, we have all the requisite assets under one roof and have built a powerful business platform set up for future growth."

The company's business model is based on seeking worthy partners and facilitating their ability to reach expanded markets. "Powered by Viatis's one-of-a-kind Global Healthcare Gateway®, our team is ready to execute on creating value for our stakeholders and partners by leveraging our unique global infrastructure to meet vast health care needs," Goettler says.

The company has a long history of successful partnerships, including its work with Gilead to help deliver infectious disease medicines to larger populations. Going forward, Viatis will seek complex, inventive, differentiated products that can leverage its commercial and technical strengths. "Biotech companies, for example, are playing a critical role in health care today. Viatis can be their Partner of Choice™ to accelerate patient access to their innovations in all corners of the world," says Goettler, who notes that Viatis offers scientific, manufacturing, regulatory, medical, and legal expertise, in addition to its commercial capabilities.

Restricted access to critical medications is an ongoing problem across the globe, and many patients will remain underserved long after the pandemic loosens its grip. Viatis is staking its future on getting them what they need. ■



GLOBAL
HEALTHCARE
GATEWAY™



VIATRIS™

FORTUNE
500
2021

Accelerate the Possibilities

Powered by VIATRIS™, the GLOBAL HEALTHCARE GATEWAY® accelerates getting medicines and healthcare solutions into the hands of those who need them most, anywhere in the world with:

- Global commercial reach across all channels
- Access to our global supply chain
- Expansive regulatory expertise
- A cost-efficient manufacturing platform

Learn how Viatis is the PARTNER OF CHOICE™ at [Viatis.com/globalhealthcaregateway](https://viatis.com/globalhealthcaregateway)